{"id":"W3195751328","doi":"10.1136/jitc-2021-002973","title":"Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Center for Advancing Translational Sciences; AstraZeneca; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"Durvalumab; Tremelimumab; Medicine; Lung cancer; PD-L1; Internal medicine; Oncology; Squamous cell cancer; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001841332,0.001527444,0.001880239,0.0004060752,0.0003938158,0.001005725,0.001075548,0.001290785,0.004264408],"category_scores_gemma":[0.001094509,0.000731496,0.001136273,0.0003153097,0.0008320597,0.0008803823,0.0004092652,0.002512984,0.001102058],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001246686,"about_ca_system_score_gemma":0.002057048,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0014636,"about_ca_topic_score_gemma":0.004746127,"domain_scores_codex":[0.9995073,0.0002579404,0.00002097324,0.00007588151,0.00004103949,0.00009687795],"domain_scores_gemma":[0.9991824,0.0001122929,0.0001447594,0.00006900899,0.00005341931,0.0004381873],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.846944,0.06485683,0.006765069,0.0005430677,0.001357313,0.0001810209,0.0003680374,0.001653903,0.02094712,0.0003655099,0.004196158,0.05182201],"study_design_scores_gemma":[0.7325187,0.2541943,0.008698558,0.00001987283,0.0002987759,0.0001569126,0.00005136072,0.001029065,0.001126138,0.0001667034,0.001721082,0.00001844718],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900647,0.001288076,0.0005830202,0.000501767,0.0001571491,0.003904203,0.001473512,0.0001000496,0.001927591],"genre_scores_gemma":[0.9862156,0.001009922,0.001692598,0.0008497108,0.0001725515,0.004477452,0.00288128,0.00003099295,0.002669814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004264408,"threshold_uncertainty_score":0.01426589,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01685992661131969,"score_gpt":0.3365914877365322,"score_spread":0.3197315611252125,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}